Comparison
CJC-1295 vs. Dulaglutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Metabolic
CAS no.
no data
923950-08-7
Molecular weight
3647.3 g/mol
59670 g/mol
Half-life
144 h
110 h
Sequence
YADAIFTNSYRKVLGQLSARKLLQDIMSR-DACGLP-1(7-37)-Variante kovalent verbunden mit modifiziertem humanen IgG4-FcMechanism of action
CJC-1295
Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.
Dulaglutide
Dulaglutide consists of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc. The Fc fusion increases molecular weight substantially (~60 kDa), reduces renal filtration and extends the half-life to several days. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon, delays gastric emptying and modulates central satiety signalling.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
3
5
of which in humans
2
5
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
3
2